OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
Michael Kreuter, Joyce Lee, Argyrios Tzouvelekis, et al.
American Journal of Respiratory and Critical Care Medicine (2021) Vol. 204, Iss. 1, pp. 74-81
Open Access | Times Cited: 147
Michael Kreuter, Joyce Lee, Argyrios Tzouvelekis, et al.
American Journal of Respiratory and Critical Care Medicine (2021) Vol. 204, Iss. 1, pp. 74-81
Open Access | Times Cited: 147
Showing 1-25 of 147 citing articles:
Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis
Benjamin J. Moss, Stefan W. Ryter, Iván O. Rosas
Annual Review of Pathology Mechanisms of Disease (2021) Vol. 17, Iss. 1, pp. 515-546
Closed Access | Times Cited: 427
Benjamin J. Moss, Stefan W. Ryter, Iván O. Rosas
Annual Review of Pathology Mechanisms of Disease (2021) Vol. 17, Iss. 1, pp. 515-546
Closed Access | Times Cited: 427
Interstitial lung diseases
Marlies Wijsenbeek, Atsushi Suzuki, Toby M. Maher
The Lancet (2022) Vol. 400, Iss. 10354, pp. 769-786
Closed Access | Times Cited: 262
Marlies Wijsenbeek, Atsushi Suzuki, Toby M. Maher
The Lancet (2022) Vol. 400, Iss. 10354, pp. 769-786
Closed Access | Times Cited: 262
Idiopathic pulmonary fibrosis: state of the art for 2023
Anna J. Podolanczuk, Carey C. Thomson, Martine Rémy‐Jardin, et al.
European Respiratory Journal (2023) Vol. 61, Iss. 4, pp. 2200957-2200957
Closed Access | Times Cited: 160
Anna J. Podolanczuk, Carey C. Thomson, Martine Rémy‐Jardin, et al.
European Respiratory Journal (2023) Vol. 61, Iss. 4, pp. 2200957-2200957
Closed Access | Times Cited: 160
Pulmonary fibrosis: from pathogenesis to clinical decision-making
Thomas Koudstaal, Manuela Funke-Chambour, Michael Kreuter, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 12, pp. 1076-1087
Closed Access | Times Cited: 67
Thomas Koudstaal, Manuela Funke-Chambour, Michael Kreuter, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 12, pp. 1076-1087
Closed Access | Times Cited: 67
Precision medicine advances in idiopathic pulmonary fibrosis
Τheodoros Karampitsakos, Brenda Juan-Guardela, Argyris Tzouvelekis, et al.
EBioMedicine (2023) Vol. 95, pp. 104766-104766
Open Access | Times Cited: 66
Τheodoros Karampitsakos, Brenda Juan-Guardela, Argyris Tzouvelekis, et al.
EBioMedicine (2023) Vol. 95, pp. 104766-104766
Open Access | Times Cited: 66
Single-Cell Profiling Reveals Immune Aberrations in Progressive Idiopathic Pulmonary Fibrosis
Avraham Unterman, Amy Zhao, Nir Neumark, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 210, Iss. 4, pp. 484-496
Open Access | Times Cited: 21
Avraham Unterman, Amy Zhao, Nir Neumark, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 210, Iss. 4, pp. 484-496
Open Access | Times Cited: 21
The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis
Angelo Zinellu, Claudia Collu, Mouhamad Nasser, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 18, pp. 4134-4134
Open Access | Times Cited: 61
Angelo Zinellu, Claudia Collu, Mouhamad Nasser, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 18, pp. 4134-4134
Open Access | Times Cited: 61
Monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) and the risk of all-cause and cardiovascular mortality: a nationwide cohort study in the United States
Ming Jiang, Jiaming Yang, Huayiyang Zou, et al.
Lipids in Health and Disease (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 52
Ming Jiang, Jiaming Yang, Huayiyang Zou, et al.
Lipids in Health and Disease (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 52
S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis
Yupeng Li, Yaowu He, Chen Shi-bin, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 43
Yupeng Li, Yaowu He, Chen Shi-bin, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 43
Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe
Τheodoros Karampitsakos, Paolo Spagnolo, Nesrin Moğulkoç, et al.
Respirology (2022) Vol. 28, Iss. 1, pp. 56-65
Closed Access | Times Cited: 42
Τheodoros Karampitsakos, Paolo Spagnolo, Nesrin Moğulkoç, et al.
Respirology (2022) Vol. 28, Iss. 1, pp. 56-65
Closed Access | Times Cited: 42
Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis
C.Y. Perrot, Τheodoros Karampitsakos, Jose D. Herazo‐Maya
AJP Cell Physiology (2023) Vol. 325, Iss. 4, pp. C1046-C1057
Open Access | Times Cited: 35
C.Y. Perrot, Τheodoros Karampitsakos, Jose D. Herazo‐Maya
AJP Cell Physiology (2023) Vol. 325, Iss. 4, pp. C1046-C1057
Open Access | Times Cited: 35
Elevated circulating monocytes and monocyte activation in COVID-19 convalescent individuals
Juwon Park, Logan S. Dean, Boonyanudh Jiyarom, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 30
Juwon Park, Logan S. Dean, Boonyanudh Jiyarom, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 30
Idiopathic pulmonary fibrosis
Thomas Koudstaal, Marlies Wijsenbeek
La Presse Médicale (2023) Vol. 52, Iss. 3, pp. 104166-104166
Open Access | Times Cited: 29
Thomas Koudstaal, Marlies Wijsenbeek
La Presse Médicale (2023) Vol. 52, Iss. 3, pp. 104166-104166
Open Access | Times Cited: 29
Interpretable and context-free deconvolution of multi-scale whole transcriptomic data with UniCell deconvolve
Daniel Charytonowicz, Rachel Brody, Robert Sebra
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 25
Daniel Charytonowicz, Rachel Brody, Robert Sebra
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 25
Emerging role of immune cells as drivers of pulmonary fibrosis
Steven E. Mutsaers, Tylah Miles, Cecilia M. Prêle, et al.
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108562-108562
Closed Access | Times Cited: 23
Steven E. Mutsaers, Tylah Miles, Cecilia M. Prêle, et al.
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108562-108562
Closed Access | Times Cited: 23
Immune mechanisms in fibrotic interstitial lung disease
Mari Kamiya, Hannah M. Carter, Milena S. Espíndola, et al.
Cell (2024) Vol. 187, Iss. 14, pp. 3506-3530
Closed Access | Times Cited: 13
Mari Kamiya, Hannah M. Carter, Milena S. Espíndola, et al.
Cell (2024) Vol. 187, Iss. 14, pp. 3506-3530
Closed Access | Times Cited: 13
The mechanism of gut-lung axis in pulmonary fibrosis
Yawei Dong, Lanlan He, Zhongbo Zhu, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 11
Yawei Dong, Lanlan He, Zhongbo Zhu, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 11
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine
Ayodeji Adegunsoye, Jonathan A. Kropski, Jürgen Behr, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 210, Iss. 4, pp. 401-423
Closed Access | Times Cited: 10
Ayodeji Adegunsoye, Jonathan A. Kropski, Jürgen Behr, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 210, Iss. 4, pp. 401-423
Closed Access | Times Cited: 10
Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis
Purnima Tiwari, Shobhit Verma, Kaveri R. Washimkar, et al.
International Immunopharmacology (2024) Vol. 135, pp. 112269-112269
Closed Access | Times Cited: 8
Purnima Tiwari, Shobhit Verma, Kaveri R. Washimkar, et al.
International Immunopharmacology (2024) Vol. 135, pp. 112269-112269
Closed Access | Times Cited: 8
Pre‐Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients
Roger M. Li, Dino B.A. Tan, Chantalia Tedja, et al.
Respirology (2025)
Open Access | Times Cited: 1
Roger M. Li, Dino B.A. Tan, Chantalia Tedja, et al.
Respirology (2025)
Open Access | Times Cited: 1
Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis
Τheodoros Karampitsakos, Sebastiano Emanuele Torrisi, Katerina M. Antoniou, et al.
Respiratory Research (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 53
Τheodoros Karampitsakos, Sebastiano Emanuele Torrisi, Katerina M. Antoniou, et al.
Respiratory Research (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 53
Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response
Willis S. Bowman, Gabrielle Echt, Justin M. Oldham
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 53
Willis S. Bowman, Gabrielle Echt, Justin M. Oldham
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 53
Neutrophil lymphocyte ratio as an indicator for disease progression in Idiopathic Pulmonary Fibrosis
Andrew Achaiah, Amila Rathnapala, Andréa Z Pereira, et al.
BMJ Open Respiratory Research (2022) Vol. 9, Iss. 1, pp. e001202-e001202
Open Access | Times Cited: 33
Andrew Achaiah, Amila Rathnapala, Andréa Z Pereira, et al.
BMJ Open Respiratory Research (2022) Vol. 9, Iss. 1, pp. e001202-e001202
Open Access | Times Cited: 33
Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis
Shiao‐Ya Hong, Yating Lu, Shih‐Yu Chen, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 6
Open Access | Times Cited: 21
Shiao‐Ya Hong, Yating Lu, Shih‐Yu Chen, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 6
Open Access | Times Cited: 21
